Background Lateral pelvic lymph-node metastases occur in 10–25% of patients with rectal
cancer, and are associated with higher local recurrence and reduced survival rates. A meta …

The presence of lateral pelvic lymph nodes (LPLN) in advanced rectal cancer entails
challenges with ongoing debate regarding the role of prophylactic dissection vs …

Background Postoperative urinary dysfunction is a major complication of rectal cancer
surgery. A randomized controlled trial (JCOG0212) concluded that the noninferiority of …

Background To compare outcomes of total mesorectal excision with or without lateral pelvic
lymph node dissection for the treatment of rectal cancer. Methods The electronic data …

Background Total mesorectal excision is the gold standard treatment of mid-and low-lying
rectal cancer. Lateral pelvic lymph node dissection has been suggested as an approach to …

In the era of neoadjuvant chemoradiotherapy/radiotherapy and total mesorectal excision,
overall oncological outcomes after curative resection of rectal cancer are excellent, with …

Lateral pelvic lymph node (LPLN) involvement occurs in 10%–25% of rectal cancer cases.
Total mesorectal excision (TME) with routine LPLN dissection (LPLND) is predominantly …

Lateral lymph node metastasis in rectal cancer was first reported in the 1950s, since then,
there has been an on-going debate about the value of lateral lymph node dissection (LLND) …

Background The long-term outcomes of minimally invasive lateral pelvic lymph node
dissection (LPND) are not completely known. The aim of this study was to compare long …

The role of lateral lymph node dissection (LLND) during total mesorectal excision (TME) for
rectal cancer is still controversial. Many reviews were published on prophylactic LLND in …